BENDER ROBERT & ASSOCIATES Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0000894300
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 39 positions · Total reported value $481.32M · Top-10 concentration 74.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 49.0% · 10 new · 11 cut · 3 exited
Active Share (vs S&P 500): 63.1% · vs QQQ: 59.6% — share of the book that differs from index weights (higher = more active) · ranking
In its Q4 2025 13F filing, BENDER ROBERT & ASSOCIATES disclosed 39 equity positions with a combined reported value of $481.32M. The filing implies a focused portfolio: its ten largest positions account for 74.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Technology Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were NVDA ($88.61M), AAPL ($77.53M), ISRG ($41.02M). By sector, the heaviest allocations are Technology 59.7%, Consumer Discretionary 20.7%. Versus the prior quarter, allocation shifted toward Health Care (+2.7pp) and away from Technology (-0.6pp), Consumer Discretionary (-2.0pp).
Versus the prior quarter, BENDER ROBERT & ASSOCIATES opened 10 new positions, trimmed 11 and fully exited 3, a turnover rate of 49.0% of positions. The portfolio's overlap with the prior quarter was 85% of names.
Of the 3 positions fully exited versus the prior quarter, the largest were JPM ($808.99K), URGN ($692.28K), RSP ($241.68K).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
No new positions this quarter.
Fully Exited (vs previous quarter)
- JPM JPMORGAN CHASE & CO · prev qtr: $808.99K · history
- URGN UROGEN PHARMA LTD · prev qtr: $692.28K · history
- RSP INVESCO S&P · prev qtr: $241.68K
- AEP AMERICAN ELEC PWR CO INC · prev qtr: $230.62K · history
- PLSE PULSE BIOSCIENCES INC · prev qtr: $205.14K · history
- BCRX BIOCRYST PHARMACEUTICALS INC · prev qtr: $179.96K · history
- EOLS EVOLUS INC · prev qtr: $153.93K · history
Insider Transactions (Form 4)
Latest BENDER ROBERT & ASSOCIATES buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Bender Robert & Associates is an SEC-registered 13F filer. As of Q2 2026 it reported 39 US equity positions with a combined value of $481.20M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 39 positions · $481.20M reported value (Q2 2026)
- Top 10 holdings = 74.4% of reported value
- Largest position: NVDA (NVIDIA CORPORATION) at 18.1%
- Average position size: $12.34M
Sector Tilt
- Information Technology 64.4%
- Consumer Discretionary 17.4%
- Health Care 14.8%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 new, 10 added, 12 reduced, 7 exited
- 16 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
475.13K | $88.61M | 18.41% | Reduce | |
| 2 |
|
285.18K | $77.53M | 16.11% | Reduce | |
| 3 |
|
72.42K | $41.02M | 8.52% | Reduce | |
| 4 |
|
130.52K | $30.13M | 6.26% | Reduce | |
| 5 |
|
37.60K | $24.82M | 5.16% | Reduce | |
| 6 |
|
11.99K | $24.16M | 5.02% | Reduce | |
| 7 |
|
69.80K | $21.90M | 4.55% | Reduce | |
| 8 |
|
17.94K | $19.28M | 4.01% | Reduce | |
| 9 |
|
57.17K | $17.90M | 3.72% | Reduce | |
| 10 |
|
62.54K | $13.39M | 2.78% | Reduce | |
| 11 |
|
21.90K | $13.25M | 2.75% | Reduce | |
| 12 |
|
26.46K | $12.00M | 2.49% | Add | |
| 13 |
|
32.69K | $10.20M | 2.12% | Reduce | |
| 14 |
|
54.82K | $10.10M | 2.10% | Add | |
| 15 |
|
1.83K | $9.81M | 2.04% | Reduce | |
| 16 |
|
62.97K | $9.65M | 2.00% | Add | |
| 17 |
|
19.91K | $9.63M | 2.00% | Reduce | |
| 18 |
|
43.33K | $9.00M | 1.87% | Hold | |
| 19 |
|
23.74K | $8.31M | 1.73% | Reduce | |
| 20 |
|
39.47K | $5.18M | 1.07% | Hold | |
| 21 |
|
7.24K | $4.73M | 0.98% | Add | |
| 22 |
|
44.73K | $3.77M | 0.78% | Hold | |
| 23 |
|
29.31K | $3.34M | 0.69% | Reduce | |
| 24 |
|
8.70K | $3.00M | 0.62% | Reduce | |
| 25 |
|
35.22K | $2.83M | 0.59% | Reduce | |
| 26 |
|
42.64K | $1.58M | 0.33% | Reduce | |
| 27 |
|
1.39K | $1.20M | 0.25% | Reduce | |
| 28 |
|
3.34K | $692.04K | 0.14% | Reduce | |
| 29 |
|
2.76K | $630.17K | 0.13% | Reduce | |
| 30 |
|
949 | $543.65K | 0.11% | Reduce | |
| 31 |
|
4.44K | $467.02K | 0.10% | Reduce | |
| 32 |
|
912 | $424.60K | 0.09% | Reduce | |
| 33 |
|
3.10K | $389.02K | 0.08% | Reduce | |
| 34 |
|
1.96K | $382.80K | 0.08% | Reduce | |
| 35 |
|
2.29K | $372.71K | 0.08% | Reduce | |
| 36 |
|
2.82K | $346.00K | 0.07% | Hold | |
| 37 |
|
868 | $304.50K | 0.06% | Reduce | |
| 38 |
|
750 | $259.57K | 0.05% | Reduce | |
| 39 |
|
1.75K | $204.88K | 0.04% | Reduce | |
FAQ
What did BENDER ROBERT & ASSOCIATES buy in 2025-Q4?
In its 2025-Q4 13F filing, BENDER ROBERT & ASSOCIATES reported 39 equity positions worth $481.32M in aggregate; its largest disclosed positions were NVDA ($88.61M), AAPL ($77.53M), ISRG ($41.02M).
How large is BENDER ROBERT & ASSOCIATES's portfolio?
BENDER ROBERT & ASSOCIATES reported $481.32M of long equity holdings across 39 positions as of 2025-Q4. Top-10 holdings account for 74.5% of reported value.
What is BENDER ROBERT & ASSOCIATES's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Technology Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.